MYCN and neoplasm: Importantly, this is the first therapeutic intervention we have shown to elicit a reduction in T1 of tumours arising in Th-MYCN and Th-MYCN/ALKF1174L mice in the absence of any tumour regression, reinforcing the potential of T1 mapping to provide an early imaging biomarker of effective treatment response in neuroblastoma.